Friday, 16 October 2026European Markets

ERAMET And ROBERTET Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(vianews) - eramet (era.pa) is among this list of stock assets with the highest dividend rate and return on equity on the basic materials sector.

financial asset price forward dividend yield return on equity
eramet (era.pa) €82.40 3.94% 51.96%
robertet (rbt.pa) €845.00 0.96% 15.94%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. eramet (era.pa)

3.94% forward dividend yield and 51.96% return on equity

eramet s.a. operates as a mining and metallurgical company in france, asia, europe, north america, and internationally. the company extracts and processes manganese ore and nickel ore; and extracts and develops mineral sands. it also produces ferronickel, nickel pig iron, briquettes, nickel salts, high purity nickel, nickel ferroalloys, and alloy steel and casting; manganese alloys, such as high-carbon ferromanganese, silicomanganese, low and medium-carbon ferromanganese, and low-carbon silicomanganese for use in batteries, pigments, construction, and automotive industries; and mineral sands, such as titanium dioxide, high-purity pig iron, zircon, and ilmenite used in ceramics and pigments. in addition, it operates moanda mine in gabon; nickel mines in new caledonia and indonesia; and mineral sand mine in senegal and argentina. eramet s.a. was incorporated in 1880 and is headquartered in paris, france.

earnings per share

as for profitability, eramet has a trailing twelve months eps of €31.63.

pe ratio

eramet has a trailing twelve months price to earnings ratio of 2.61. meaning, the purchaser of the share is investing €2.61 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 51.96%.

revenue growth

year-on-year quarterly revenue growth grew by 10.3%, now sitting on 5.1b for the twelve trailing months.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jun 3, 2022, the estimated forward annual dividend rate is 3.5 and the estimated forward annual dividend yield is 3.94%.

yearly top and bottom value

eramet's stock is valued at €82.40 at 02:30 est, way under its 52-week high of €148.90 and way higher than its 52-week low of €60.60.

more news about eramet.

2. robertet (rbt.pa)

0.96% forward dividend yield and 15.94% return on equity

robertet sa produces and sells perfumes, aromas, and natural products. the company operates in three segments: raw materials, fragrances, and flavors. it also produces organic essential oils and active ingredients. the company operates in north america, europe, the asia pacific, south america, caribbean, africa, and the middle east. robertet sa was founded in 1850 and is headquartered in grasse, france.

earnings per share

as for profitability, robertet has a trailing twelve months eps of €36.98.

pe ratio

robertet has a trailing twelve months price to earnings ratio of 22.85. meaning, the purchaser of the share is investing €22.85 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.94%.

more news about robertet.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com